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ORIGINAL ARTICLE
Background/Aims: The efficacy and safety of pemetrexed, gefitinib, and erlotinib administration in previously
treated patients with non-small cell lung cancer (NSCLC) were compared.  
Methods: The study patients met the following criteria: histologically confirmed, previously treated advanced
(stage IIIB or IV) or recurrent NSCLC; a measurable lesion; ≥ 18 years of age; Eastern Cooperative Oncology
Group Performance status 0 to 2; and no prior exposure to the three study drugs. Patients received 500 mg/m2
of pemetrexed intravenously every 3 weeks with vitamin supplementation, gefitinib (250 mg/day per os), or
erlotinib (150 mg/day per os).  
Results: Of 57 patients (pemetrexed, 20; gefitinib, 20; and erlotinib, 17), 55 were evaluated for a response. The
numbers of males, smokers, and squamous histology were increased in the pemetrexed group compared to the
other groups. The objective response rates were 5.3%, 25.0%, and 12.5% (p = 0.22), and the disease control
rates (DCR) were 5.3%, 40.0%, and 50.0%, respectively (p < 0.01). The median progression-free survival (PFS)
was 1.7, 3.5, and 4.4 months (p < 0.01) and the median overall survival (OS) was 5.6, 21.8, and 21.5 months
(p = 0.04), respectively. In subgroup analyses, patients with non-squamous histology, males, and a smoking history
had a higher DCR and longer PFS with gefitinib and erlotinib than with pemetrexed. All three chemotherapeutic
agents had manageable toxicities. 
Conclusions: Both oral epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) had comparable
efficacy and safety. The superior PFS and OS of EGFR TKIs with more favorable baseline clinical characteristics
than those of pemetrexed suggest the impact of baseline clinicopathological factors. (Korean J Intern Med
2010;25:294-300)
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INTRODUCTION
Lung cancer represents the leading cause of cancer
deaths in Korea [1] and Western countries [2]. Non-small
cell lung cancer (NSCLC) accounts for approximately 75%
of lung cancers [3]. About 50% of NSCLC patients are
initially diagnosed with advanced or metastatic disease,
and the treatment of choice is palliative chemotherapy.
Platinum doublets have superior treatment outcomes over
single-agent chemotherapy, and are regarded as standard
first-line treatment in advanced NSCLC [4-6]. Although
lung cancer has a dismal prognosis, a substantial percentage
of patients progress after first-line treatment with good
performance status (PS) and adequate organ function.
Further salvage treatment should be considered [3].
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in patients with advanced NSCLC [7], several other drugs
were evaluated for their efficacy and safety as potential
substitutes. Pemetrexed (Alimta®; Eli Lilly and Company,
Indianapolis, IN, USA) is a multi-targeted anti-folate
compound. A randomized phase III trial demonstrated
non-inferiority of pemetrexed to docetaxel with fewer
grade 3 or 4 toxicities [8]. Erlotinib (Tarceva®; Genentech,
San Francisco, CA, USA and OSI Pharmaceuticals,
Melville, NY, USA) is an oral epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR TKI). A phase III
BR.21 study [9] compared erlotinib with best supportive
care (BSC) in 731 advanced NSCLC patients. A higher
progression-free survival (PFS) and overall survival (OS)
was shown in patients treated with erlotinib compared to
BSC. Gefitinib (Iressa®; AstraZeneca, Wilmington, DE,
USA) is another EGFR TKI that was safe and efficacious
at a dose of 250 mg/day in a large-scale phase II trial in
patients with advanced NSCLC who had undergone a
previous treatment regimen [10]. Although a phase III
study by Thatcher et al. [11] failed to demonstrate the
superiority of gefitinib over BSC, the subsequent phase III
IRESSA NSCLC Trial Evaluating Response and Survival
against Taxotere (INTEREST) study [12], which compared
gefitinib with docetaxel, reported that gefitinib had similar
clinical outcomes, with better tolerability and more
convenient administration than docetaxel in previously
treated patients with advanced or metastatic NSCLC who
had failed platinum-based chemotherapy. Although these
drugs were approved and have been commonly used as
second-line or salvage therapy in patients with NSCLC,
data directly comparing pemetrexed and EGFR TKIs are
limited [13]. Therefore, this study compared the efficacy
and safety of three agents in previously treated patients
with NSCLC.
METHODS
Patients
Previously treated patients with advanced NSCLC at
a single institution (Gachon University Gil Hospital,
Incheon, Korea) were analyzed retrospectively. Eligibility
for the study included the following: histologically or
cytologically confirmed NSCLC; ≥ 18 years of age with
advanced (stage IIIB or IV) or recurrence at initial diagnosis;
Eastern Cooperative Oncology Group (ECOG) PS 0 to 2;
at least one measurable lesion; previous chemotherapy
without exposure to the three study drugs; and adequate
marrow and organ function. This study was reviewed and
approved by the Institutional Review Board of Gachon
University Gil Hospital.
Treatment
Patients in the pemetrexed group were administered
500 mg/m2 of pemetrexed mixed with 100 mL of normal
saline as a 10-minute intravenous infusion on day 1 every
3 weeks. Patients in the gefitinib group received gefitinib
(250 mg per os [PO] daily), and patients in the erlotinib
group received erlotinib (150 mg PO daily). Cycles were
repeated until disease progression, unacceptable toxicity,
or the patient declined further treatment. Patients in the
pemetrexed group were instructed to take folic acid (1 mg
orally daily) from day 7 of the first cycle to the end of
pemetrexed treatment and a vitamin B12 (1,000 µg) was
injected intramuscularly 1 week before the first dose of
pemetrexed in the first cycle, and then every three
chemotherapy cycles. A delay of the next cycle for up to 21
days was permitted. For erlotinib, one dose reduction per
patient from 150 to 100 mg was permitted in the case of
grade 3 or 4 diarrhea or skin reactions.
Evaluation of the tumor response and toxicity
Response Evaluation Criteria in Solid Tumor (RECIST)
version 1.0 [14] was used to evaluate the response. Chest
computed tomography (CT) and other modalities to
evaluate measurable or evaluable lesions were performed
within 2 weeks before treatment initiation and every two
cycles of pemetrexed or every 2 months of EGFR TKI
therapy. Common Terminology Criteria for Adverse Event
(CTCAE) version 3.0 [15] was used to identify adverse
events. 
Statistical consideration
We analyzed the PFS, response rates (RRs), disease
control rates (DCRs; the sum of complete response, partial
response, and stable disease, as defined by RECIST),
safety profiles of each group, and PFS according to clinical
characteristics.
Fisher’s exact test was applied to compare response
rates and toxic effects between treatments. The Kaplan-
Meier method was used for survival analysis. The log-rank
test was performed for univariate analysis of survival, and
variables showing an association with survival on univariate
analysis with p< 0.1 were included in multivariate analysis
using Cox proportional hazard regression models.296 The Korean Journal of Internal Medicine Vol. 25, No. 3, September 2010
RESULTS
Patient characteristics
Between September 2005 and August 2008, 57 patients
received pemetrexed (n = 20), gefitinib (n = 20), or erlotinib
(n = 17). The patient characteristics were balanced, except
for the number of cigarette smokers, which was more
common in the pemetrexed group (Table 1). The median
number of chemotherapy cycles administered was 2
(range, 1 to 4) in the pemetrexed group. The median
duration of treatment was 3.2 months (range, 0.8 to 18.3)
and 4.4 months (range, 0.5 to 17.5) for patients receiving
gefitinib and erlotinib, respectively. 
Evaluation of tumor response and survival
Two of 57 patients (one each for pemetrexed and
gefitinib) were not evaluated for treatment response. The
objective RR was 5.3% for pemetrexed, 25% for gefitinib,
and 12.5% for erlotinib (p= 0.22). The DCR of pemetrexed,
gefitinib, and erlotinib was 5.3%, 40.0%, and 50.0%,
respectively (p < 0.01). No patient in the pemetrexed
Table 1. Patient characteristics
Characteristics Pemetrexed Gefitinib Erlotinib p value
(n = 20) (n = 20) (n = 17)
Gender
Male 17 9 11 0.17
Female 3 11 6
Age, yr
Median (range) 62 (38 - 74) 61 (43 - 73) 67 (45 - 77) 0.60
< 60 7 10 7
≥ 60 13 10 10
Performance status
0 2 2 3 0.83
11 4 1 3 1 2
24 5 2
Smoking status
Current or ever-smoker 19 9 8 < 0.01
Never-smoker 1 11 9
Pathologic subtype
Squamous cell carcinoma 9 4 3 0.14
Non-squamous cell carcinoma 11 16 14
Adenocarcinoma 6 14 12
Large-cell carcinoma 1 1 0
Non-small cell carcinoma 4 1 2
Initial stage
IIIB 5 8 4 0.58
IV 15 12 13
Response to prior therapy
Complete/partial response 11 12 7 0.27
Stable disease 6 1 2
Progressive disease 3 4 6
Not evaluation 0 3 2
Treatment sequence
2nd-line 13 10 10 0.91
≥ 3rd-line 7 10 7
Prior chemotherapy
Platinum-based therapy 18 17 15 0.61
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group maintained a partial response (PR) or stable disease
defined by the RECIST criteria for at least 1 month, except
for one patient with a PR.
The median duration of follow-up was 12.1 months.
Fifty-two patients had disease progression (20 in the
pemetrexed, 19 in the gefitinib, and 13 in the erlotinib
groups) and 20 patients died (8 in the pemetrexed, 7 in
the gefitinib, and 5 in the erlotinib groups). The median
PFS in the pemetrexed, gefitinib, and erlotinib groups was
1.7, 3.5, and 4.4 months, respectively (p< 0.01). The median
OS was 5.6, 21.8, and 21.5 months in the respective groups
(p = 0.04). Fig. 1 shows the Kaplan-Meier curves for PFS
and OS.
Based on univariate analysis, patients administered an
EGFR TKI, female, and no cigarette smoking had a
significantly better PFS. Multivariate analysis revealed
that only the use of an EGFR TKI contributed indepen-
dently to prolonging the PFS (Table 2). There was no
significant difference in the RR (p = 0.43), DCR (p =
0.74), and PFS (p = 0.43) between patients treated with
gefitinib and erlotinib.
The DCRs of patients treated with gefitinib or erlotinib
were also higher among patients with non-squamous
carcinoma (p < 0.01), male gender (p = 0.02), cigarette
smokers (p = 0.02), patients with a good performance
status (0 or 1; p< 0.01), patients with a good prior response
(p < 0.01), and patients ≥ 60 years of age (p = 0.03) than
patients treated with pemetrexed. Analysis of the PFS
according to clinical factors is summarized in Table 3.
Twelve of 20 patients in the gefitinib group and 10 of
17 patients in the erlotinib group received subsequent
pemetrexed as a salvage treatment after progression.
Three of these 22 patients achieved a partial response
(PR); however, the response lasted for less than 1 month.
Figure 1. Kaplan-Meier curves of the (A) progression-free and (B) overall survival of patients treated with pemetrexed, gefitinib, and
erlotinib.
A B
Table 2. Univariate and multivariate analyses of the progression-free survival
Univariate analysis Multivariate analysis
p value HR (95% CI) p value
EGFR TKI (yes/no) < 0.01 0.32 (0.16 - 0.63) < 0.01
Gender (male/female) 0.03 1.16 (0.35 - 3.82) 0.81
Age (< 60/ ≥ 60) 0.28
Smoker (yes/no) < 0.01 1.49 (0.43 - 5.23) 0.81
Pathology (non Sq./Sq.) 0.17
ECOG PS (0,1/2) 0.17
Previous response. (non PD/PD) 0.85
HR, hazard ratio; CI, confidence interval; EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; Sq., squamous cell
carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease.298 The Korean Journal of Internal Medicine Vol. 25, No. 3, September 2010
In the pemetrexed group, 16 of 20 patients received
gefitinib (2 of 16) or erlotinib (14 of 16) as salvage therapy
after progression; only one patient had a PR with a
duration of response of 4.5 months.
Toxicity
All treated patients (n = 57) were assessable for toxicity.
Of the erlotinib group, 11.7% required a dose reduction
because of drug-related toxic effects. The median number
of chemotherapy cycles administered was 2 (range, 1 to 9)
in the pemetrexed group. The median duration of treatment
was 3.2 months for the pemetrexed group, and 4.4
months for the patients receiving gefitinib and erlotinib.
One patient in the gefitinib group and three patients in the
erlotinib group discontinued EGFR TKI because of severe
or prolonged non-hematologic toxicity (one patient for
diarrhea in the gefitinib group and three patients for skin
rashes in the erlotinib group). The frequently reported
toxicities in the gefitinib and erlotinib groups were skin
disorders (rash, dry skin, pruritus, and acne), diarrhea,
and anorexia. The toxicity profiles are shown in Table 4.
DISCUSSION
In contrast to pemetrexed [8] and gefitinib [12], which
were not inferior to docetaxel in a large phase III trial,
there are no reported clinical trials that directly compare
erlotinib with docetaxel. Instead, erlotinib was approved
as a second- or third-line agent based on the result of the
BR21 study [9] comparing erlotinib with placebo. In BR21,
the median OS and median PFS improved significantly
with erlotinib (6.7 vs. 4.7 months for OS; p = 0.002 and
2.2 vs. 1.8 months for PFS; p< 0.001). In our study, erlotinib
was efficacious and safe, comparable to the other EGFR
TKI, gefitinib. There was no difference in the baseline
characteristics, RRs, DCRs, or survivals between the
gefitinib and erlotinib arms.
No prospective trials have reported the results of a
comparison between pemetrexed and EGFR TKIs after
the failure of first-line chemotherapy. Although treatment
with gefitinib or erlotinib was associated with longer
survival in our study, the result should be interpreted
cautiously because our study has several limitations. The
numbers of patients in each group were not large enough
for a conclusive analysis and the baseline patient
characteristics were not stratified homogeneously in this
Table 3. Analysis of the progression-free survival according to clinical factors
No. Pemetrexed (P) Gefitinib (G) Erlotinib (E) p value EGFR TKI p value
Median, mon P vs. G P vs. E P vs. G+E
Pathologic subtype
Squamous 16 1.7 2.8 2.6 0.17 0.62 2.8 0.19
Non-squamous 41 1.7 3.55 5.4 < 0.01 < 0.01 5.4 < 0.01
Gender
Male 37 1.7 5.7 2.8 < 0.01 < 0.01 2.9 < 0.01
Female 20 2.1 3.5 5.4 0.27 0.03 5.4 0.1
Smoking status
Smoker 36 1.7 5.7 2.6 < 0.01 0.02 4.4 < 0.01
Non-smoker 21 4.1 3.5 5.4 0.83 0.64 4.0 0.73
Age, yr
Age ≥ 60 32 1.7 3.5 2.7 < 0.01 0.01 2.8 < 0.01
Age < 60 25 1.5 3.1 14.2 0.02 < 0.01 9.4 < 0.01
Performance status
ECOG 0 or 1 46 1.7 6.1 7.1 < 0.01 < 0.01 6.1 < 0.01
ECOG 2 11 1.1 3.1 2.6 0.26 0.71 3.1 0.30
Response to prior treatment
Non-PD 40 1.7 3.5 7.0 < 0.01 < 0.01 5.7 < 0.01
PD 13 1.5 2.8 4.0 0.27 0.24 4.0 0.17
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PD, progressive
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study. The numbers of male patients, smokers, and
squamous cell carcinoma were higher in the pemetrexed
arm than in the other groups, although the differences
were not significant, except for smoking. Many previous
studies reported good efficacy and improved survival of
both EGFR TKIs for ethnic Asians, women, non-smokers,
and non-squamous histology [9-11,16,17]. Based on these
results, the Korean Health Insurance Review & Assessment
Service accepted the use of EGFR TKIs as second-line
treatment if at least two of the following three are
satisfied: female gender, adenocarcinoma, and non-
smoker [18]. As this was a retrospective study that analyzed
previously treated NSCLC patients who underwent
salvage chemotherapy in clinical practice without specific
standards for the use of one of the three drugs, the criteria
of the Korean Health Insurance Service for EGFR TKIs
probably affected the heterogeneous patient characteristics
because TKIs are more convenient as they do not need
intravenous administration, unlike pemetrexed.
The larger number of patients with squamous histology
might also be a disadvantage for the pemetrexed arm.
Pemetrexed shows higher efficacy in advanced NSCLC
with non-squamous histology. In a prospective phase III
study [19], cisplatin with pemetrexed conferred similar
efficacy with better tolerability than cisplatin with
gemcitabine as first-line chemotherapy in advanced
NSCLC. In this large-scale (1,725 patients) study, the OS of
the patients with adenocarcinoma or large cell carcinoma
histology on cisplatin in the pemetrexed arm was
significantly longer than the OS of patients with the same
histology on cisplatin with gemcitabine (for adenocarcinoma,
median 12.6 vs. 10.9 months, p = 0.03; for large cell
carcinoma, median 10.4 vs. 6.7 months, p = 0.03). By
contrast, for patients with squamous cell carcinoma,
cisplatin with pemetrexed had a slightly shorter OS than
cisplatin with gemcitabine (median 9.4 vs. 10.8 months,
respectively, p = 0.05). This difference in the clinical
characteristics probably contributed to the substantially
poorer tumor response and disease control in this study
(Eighteen of 19 evaluable patients had progressive disease
as their best response after pemetrexed), compared to the
previous study [8]. A hypothesis generated by this study
is “baseline clinicopathological characteristics have
substantial effects on clinical outcomes” rather than
“EGFR TKIs are superior to pemetrexed.”
Of the 41 patients with non-squamous carcinoma, a
longer PFS in patients treated with gefitinib or erlotinib
than pemetrexed (p < 0.01) was observed. This may
reflect 4 of 11 (36.4%) ‘non-small cell carcinomas’ in which
further detailed pathology could not be determined. In the
patients with squamous carcinoma, the outcomes were
universally poor, and no superiority of TKIs was shown.
Table 4. Toxicity profiles
Pemetrexed Gefitinib Erlotinib
(n = 20) (n = 20) (n = 17)
No. (grade 1 to 4/grade 3 to 4)a 20 20 17
Hematologic toxicity
Anemia 6 / 0 3 / 0 2 / 0
Neutropenia 2 / 1 0 / 0 1 / 0
Thrombocytopenia 2 / 0 1 / 0 0 / 0
Non-hematologic toxicity
Fatigue 5 / 1 0 / 0 2 / 0
Anorexia 4 / 1 2 / 0 1 / 0
Nausea/vomiting 2 / 0 2 / 0 0 / 0
Constipation 2 / 0 0 / 0 0 / 0
Diarrhea 0 / 0 3 / 0 5 / 3
Stomatitis 1 / 0 1 / 1 0 / 0
Skin disorders 1 / 0 7 / 0 10 / 3
Edema 1 / 0 0 / 0 0 / 0
Total bilirubin 0 / 0 0 / 0 3 / 0
Alkaline phosphatase 3 / 0 0 / 0 1 / 0
Infection 2 / 0 1 / 0 1 / 0
aAccording to the National Cancer Institute-Common Toxicity Criteria, version 3.0.300 The Korean Journal of Internal Medicine Vol. 25, No. 3, September 2010
Superiority of TKIs was also observed in patients with a
good PS, a good prior response, male gender, or cigarette
smokers, although the interpretation should be made with
caution because the results of univariate or multivariate
analysis have limitations with a small sample size.
Since no head-to-head comparison with docetaxel exists,
second-line treatment of advanced NSCLC with erlotinib
remains controversial in the UK [13]. The results are
pending for a randomized trial with erlotinib as second-
line treatment versus docetaxel or pemetrexed (Tarceva in
Treatment of Advanced NSCLC [TITAN study]). The
accumulation of clinical data and the application of
genetic mutational analysis will enable more efficacious
and tailored therapy in patients with advanced NSCLC.
In summary, this retrospective study showed that both
oral EGFR TKIs had comparable efficacy with manageable
toxicities. The comparison between pemetrexed and the
EGFR TKIs was limited by the heterogeneous baseline
patient characteristics. The superior PFS and OS of the
patients with EGFR TKIs with more favorable clinical
factors compared to those of the patients with pemetrexed
reflects the effect of baseline characteristics and underlines
the necessity of patient selection according to baseline
clinicopathological factors for optimal treatment in
advanced NSCLC. 
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